Key result
This mini-review highlights the pharmacological properties, supporting evidence, and potential advantages and disadvantages of new direct oral anticoagulants compared to vitamin K antagonists.
This mini-review summarizes the pharmacological properties, supporting evidence, and potential clinical advantages and disadvantages of direct oral anticoagulants compared to vitamin K antagonists.
For the past five decades, vitamin K antagonists (VKA) have been the only class of oral anticoagulants available for treating or preventing venous and arterial thromboembolism. Recently, new oral anticoagulants were developed to address significant restrictions regarding the use of VKAs. These drugs act by direct blockade of activated coagulation factor X (FXa) or thrombin. This present mini-review highlights the pharmacological properties of these new anticoagulants, and discusses the supporting evidence for their usage as well as points to potential advantages and disadvantages of using these novel drugs in clinical practice.
No takes yet. Share an insight, caveat, or question.
Saad et al. (2015) conducted a review in Venous and arterial thromboembolism. Direct oral anticoagulants vs. Vitamin K antagonists was evaluated. This mini-review highlights the pharmacological properties, supporting evidence, and potential advantages and disadvantages of new direct oral anticoagulants compared to vitamin K antagonists.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: